Shares of Outlook Therapeutics (OTLK) were up Friday after the biopharmaceutical company reported a loss of $4.06 per share for fiscal 2024, narrowing from a loss of $4.72 a year earlier.
Six analysts surveyed by FactSet estimated a loss of $4.91 per share.
The company didn't report any revenue for the year ended Sept. 30.
Price: 1.96, Change: +0.26, Percent Change: +15.35
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。